Physician practice acquisitions carry a regulatory layer that standard business transactions do not. Corporate Practice of Medicine rules, Medicare and Medicaid provider number transfers, Stark Law compliance, and payor credentialing timelines all affect whether a deal closes cleanly and the practice keeps running. Our Haverford medical practice attorneys guide physicians buying and selling practices across Education, Healthcare, Finance and the healthcare sector, with Managing Partner Alex Lubyansky personally involved in every engagement.
Share the basics. Alex reviews every inquiry personally.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
Alex Lubyansky handles medical practice acquisition law work for buyers and sellers in Haverford and across the country. Here is what that looks like:
We work best with people who know what they want and are ready to move:
Tell us what you are working on. We respond within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
A structured, methodical approach to medical practice acquisition law
We assess the CPOM posture, Stark and AKS exposure, CON requirements, and Medicare and Medicaid provider number transfer mechanics for your specific transaction before any term sheet is signed.
Managing Partner Alex Lubyansky structures the acquisition to respect CPOM limits, optimize risk and tax treatment, and where needed designs an MSO or friendly-PC arrangement that preserves clinical independence while delivering the economic deal.
We conduct diligence across payor contracts, Medicare and Medicaid enrollment, compliance program maturity, malpractice history, physician employment agreements, and patient volume concentrations to surface risks before closing.
We negotiate the purchase agreement, physician employment or non-compete terms, transition services arrangement, and earnout provisions tied to clinical performance metrics specific to the practice type.
We coordinate CHOW filings, payor credentialing timelines, and post-closing integration to ensure patient care and reimbursement continue without interruption from day one of your ownership.
We don't take every matter. Here is what happens when you reach out.
Alex reviews your transaction details personally. No intake coordinators, no junior associates screening your submission.
We evaluate whether your deal aligns with our practice. Not every matter is a fit, and we will tell you directly if it is not.
If there is alignment, Alex schedules a direct call to discuss your transaction, timeline, and objectives.
Before any work begins, you receive a written engagement letter with defined scope, timeline, and fee structure. No surprises.
Alex Lubyansky handles every medical practice acquisition law engagement personally.
15+ years of M&A experience. Nationwide. One attorney on every deal.
We review every transaction inquiry within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
Use these before you call any firm, including ours.
At many firms, a partner sells the work and a junior associate does it. Ask for the name of the attorney who will draft and negotiate your documents.
Volume indicates current, active deal experience, not just credentials from years ago.
A $500K SBA acquisition and a $50M PE deal require different skill sets. Make sure the attorney has handled transactions similar to yours.
M&A transactions require a team. Your attorney should work with your other advisors, not in a silo.
Reps, warranties, and indemnification claims surface months after closing. Ask whether the firm handles post-closing litigation or refers it out.
Ask how the engagement is scoped, what is included, and what factors drive cost increases. Defined scope with a retainer gives the clearest cost picture.
Common questions from Haverford clients
Submit your transaction details for a preliminary assessment by our managing partner
Submit Transaction DetailsSubmit transaction details and Alex will respond directly.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
Philadelphia's M&A market is anchored by healthcare (home to more medical schools than any other US city), pharmaceutical manufacturing, and financial services. The region's strength in cell and gene therapy - centered around the University of Pennsylvania and CHOP - creates cutting-edge biotech acquisition targets. The city's industrial legacy means a deep pool of established manufacturing and distribution businesses available for acquisition.
Philadelphia offers access to high-quality targets at valuations 15-25% below comparable New York businesses, making it attractive for PE firms and strategic acquirers seeking value. The region's aging business owner demographics suggest accelerating deal flow in the coming years.
Philadelphia's location between New York and Washington DC, combined with significantly lower operating costs, makes acquired businesses well-positioned for growth across the entire Northeast corridor.
Pennsylvania does not have a specific non-compete statute - courts evaluate reasonableness on a case-by-case basis using common law standards, and the state's Bulk Sales Act has been repealed, simplifying asset purchase transactions.
Local Market Context
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD MSA · MSA population 6.2M
MSA Population (2024)
6.2M
U.S. Census Bureau
Top Industry Concentration
Philadelphia's M&A market is anchored by life sciences and pharmaceuticals, financial services, and healthcare systems. The metro is home to a large concentration of pharmaceutical and biotech firms, making it one of the most active life sciences M&A markets outside of Boston and San Francisco. Wilmington, Delaware's presence within the MSA adds a corporate domicile dimension, as many companies incorporated in Delaware are managed from the Philadelphia metro.
Philadelphia International Airport serves the metro. The Port of Philadelphia handles bulk cargo. The metro sits at the midpoint of the Northeast Corridor Amtrak rail line between New York and Washington.
Recent Haverford Deal Signal (2024-2025)
Life sciences consolidation remained active in the Philadelphia metro through 2024, with biotech and specialty pharmaceutical acquisitions by large pharma buyers a consistent theme. Cencora (formerly AmerisourceBergen) continued its acquisition strategy in pharmaceutical distribution.
Source (accessed 2026-04-27)
Pennsylvania Securities Commission oversees Blue Sky filings. Delaware corporate law applies to most M&A transactions regardless of where parties are physically located, given Delaware incorporation prevalence.
Enforceable with reasonableness test. Reformation available. Continued employment is sufficient consideration.
Entity mergers and conversions must be filed with the Pennsylvania Department of State. Tax clearance certificates (from the Department of Revenue and Department of Labor & Industry) are required for asset purchases. Annual reports are required for foreign entities (decennial reports for domestic corporations).
Pennsylvania Bar Association. Voluntary bar. The Pennsylvania Supreme Court handles attorney admission separately via the Pennsylvania Board of Law Examiners.
Bar association websiteFederal districts: E.D. Pa., M.D. Pa., W.D. Pa.
Business court: Pennsylvania Court of Common Pleas Commerce Case Management Program (established 2000) Commerce programs operate in Philadelphia County (first commerce program court) and Allegheny County (Pittsburgh). Handles complex commercial and business disputes.
Pennsylvania M&A is concentrated in Philadelphia (pharmaceuticals, financial services, healthcare) and Pittsburgh (technology, healthcare, energy), with significant mid-market deal activity statewide.
Watchpoints
These are the items we see derail medical practice acquisition law transactions in the Haverford market. Each one is rooted in current statutory law, recent legislative changes, or recurring patterns from the deals Alex has handled.
Enforceable with reasonableness test. Reformation available. Continued employment is sufficient consideration.
"The seller isn't your enemy, but their interests aren't aligned with yours."
Pennsylvania Securities Commission oversees Blue Sky filings. Delaware corporate law applies to most M&A transactions regardless of where parties are physically located, given Delaware incorporation prevalence.
Securities regulated by Pennsylvania Securities Commission (psc.pa.gov). Pennsylvania follows a comprehensive securities act with merit review authority for certain public offerings; Blue Sky notice filings required for Reg D.
In-depth guides to help you prepare for your transaction
Full-service M&A counsel from letter of intent through closing.
Read guideA structured approach to legal, financial, and operational due diligence.
Read guideUnderstanding the binding and non-binding elements of each document.
Read guideCommon deal-killers and how experienced counsel helps prevent them.
Read guideAcquisition Stars represents clients across Pennsylvania and nationwide. Alex Lubyansky handles every engagement personally.
Don't see your city? View all Medical Practice Attorney service areas or contact us directly.
"What happens in the 48 hours after 'best and final' is what actually sets the price."
15+ years of M&A and securities transaction experience Senior counsel on every engagement Admitted in Michigan, practicing nationwide
Reviewed by Alex Lubyansky on . Read full bio
Alex Lubyansky handles every engagement personally. Tell us about your transaction and we will let you know if there is a fit.
Tell us about your deal. We review every submission and respond within one business day.
Your transaction details are under review. If there is alignment, we will be in touch.
Meanwhile, feel free to call us directly at (248) 266-2790
One attorney on every deal. Nationwide. 15+ years of M&A experience.